雪榕生物(300511) - 2021 Q2 - 季度财报(更正)

Financial Performance - The company's operating revenue for the reporting period was ¥928,810,813.47, a decrease of 6.73% compared to ¥995,800,104.43 in the same period last year[4] - The net profit attributable to shareholders was a loss of ¥70,702,210.37, representing a decline of 145.48% from a profit of ¥155,466,147.74 in the previous year[4] - Basic and diluted earnings per share were both -¥0.16, a decrease of 144.44% compared to ¥0.36 in the previous year[5] Cash Flow - The net cash flow from operating activities was ¥51,797,697.21, down 80.88% from ¥270,882,499.62 in the same period last year[5] Assets and Liabilities - The total assets at the end of the reporting period were ¥4,311,699,860.85, a decrease of 5.19% from ¥4,547,783,435.53 at the end of the previous year[5] - The net assets attributable to shareholders were ¥1,900,602,599.20, down 5.78% from ¥2,017,187,114.89 at the end of the previous year[5] - The company's asset-liability ratio was 55.97%, slightly up from 55.89% at the end of the previous year[11] Financial Ratios - The EBITDA interest coverage ratio was 2.38, down from 8.77 in the same period last year[11] Dividends and Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares for the reporting period[1] - There were no changes in the controlling shareholder or actual controller during the reporting period[7]